2025 Original Papers / 2025 原著論文
- Srinivasan, S.; Koyanagi, I.; Vergara, P.; Wang, Y.; Ohba, A.; Naoi, T.; Vogt, K. E.; Chérasse, Y.; Kutsumura, N.; Sakurai, T.; Tezuka, T.; Sakaguchi, M.
“Transient reactivation of small ensembles of adult-born neurons during REM sleep supports memory consolidation in mice”
Nat. Commun. 2025, 16, 7210. (web) - Sugai, T.; Nakamura, K.; Kutsumura, N.
“Practical and unified synthesis of prenylated phenylpropanoids via O-reverse prenylation/Claisen rearrangement”
Chem. Lett. 2025, 54, upaf105. (web) - Yoshioka, T.; Kimiki, S.; Yamazaki, M.; Hamano, T.; Ou, M.; Ode, Y.; Ehara, R.; Kajino, K.; Kasai, S.; Yoshizawa, K.; Saitoh, T.; Yamada, D.; Nagase, H.; Saitoh, A.
“Agonists of the opioid δ-receptor improve irritable bowel syndrome-like symptoms via the central nervous system”
Br. J. Pharmacol. 2025, 182, 1599-1609. (web) - Pokhrel, S.; Heo, G.; Mathews, I.; Yokoi, S.; Matsui, T.; Mitsutake, A.; Wakatsuki, S.; Mochly-Rose, D.
“A hidden cysteine in Fis1 targeted to prevent excessive mitochondrial fission and dysfunction under oxidative stress”
Nat. Commun. 2025, 16, 4187. (web) - Yoshioka, T.; Yamada, D.; Hagiwara, A.; Kajino, K.; Iio, K.; Saitoh, T.; Nagase, H.; Saitoh, A.
“Delta opioid receptor agonists activate PI3K–mTORC1 signaling in parvalbumin-positive interneurons in mouse infralimbic prefrontal cortex to exert acute antidepressant-like effects”
Mol. Psychiatry 2025, 30, 2038-2048. (web) - Kajino, K.; Sugai, T.; Kakumoto, T.; Kise, R.; Suzuki, R.; Tokuda, A.; Sekiya, Y.; Katamoto, R.; Kutsumura, N.; Nagumo, Y.; Hirokawa, T.; Inoue, A.; Saitoh, T.
“Structure–Signal Relationships of the δ-Opioid-Receptor (DOR)-Selective Agonist KNT-127—Part II: Quinoline Ring Modifications for Enhanced G-Protein Signaling and Reduced β-Arrestin Recruitment”
Chem. Pharm. Bull. 2025, 73, 336-348. (web) - Kajino, K.; Sugai, T.; Kise, R.; Suzuki, R.; Tokuda, A.; Sekiya, Y.; Kakumoto, T.; Katamoto, R.; Kutsumura, N.; Nagumo, Y.; Inoue, A.; Saitoh, T.
“Structure–Signal Relationships of the δ-Opioid-Receptor (DOR)-Selective Agonist KNT-127—Part I: Impact of the Morphinan Skeleton on the G-Protein-Biased DOR Agonism”
Chem. Pharm. Bull. 2025, 73, 246-256. (web) - Yoshioka, T.; Kimiki, S.; Yamazaki, M.; Hamano, T.; Ou, M.; Ode, Y.; Ehara, R.; Kajino, K.; Kasai, S.; Yoshizawa, K.; Saitoh, T.; Yamada, D.; Nagase, H.; Saitoh, A.
“Agonists of the opioid δ‐receptor improve irritable bowel syndrome‐like symptoms via the central nervous system”
Br. J. Pharmacol. 2025, 182, 1599-1609. (web) - Arai, K.; Ono, Y.; Hirai, N.; Sugiura, Y.; Kaneko, K.; Matsuda, S.; Iio, K.; Kajino, K.; Saitoh, T.; Wei, F.-Y.; Katagiri, H.; Inoue, A.
“Chemogenetic activation of hepatic G12 signaling ameliorates hepatic steatosis and obesity”
BBA-Molecular Basis of Disease, 2025, 1871, 167566. (web)
